Ligand Pharmaceuticals Incorporated: Business Overview, Financials & Competitive Analysis
Ligand Pharmaceuticals Incorporated scores 7/10 on the AskCyborg Cyborg Score (Strong). Diversified royalty-based pharmaceutical investing platform with strong growth momentum and significant capital deployment capacity positioned for 23%+ CAGR through 2030. The company delivered robust financial performance in 2025 driven by full year royalty revenue growth of 48%. 2026 revenue guidance projects $245-285 million with 15% core revenue growth, while.
What is Ligand Pharmaceuticals Incorporated's industry? Ligand Pharmaceuticals Incorporated (ligand.com) operates in Biopharmaceutical Royalty Investing & Technology Licensing. AskCyborg classifies Ligand Pharmaceuticals Incorporated under Biopharmaceutical Royalty Investing & Technology Licensing in its company registry.
Ligand Pharmaceuticals invests in the clinical development and commercialization of high-value medicines while managing one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry wit...
Cyborg Score thesis
Diversified royalty-based pharmaceutical investing platform with strong growth momentum and significant capital deployment...
Read the full analyst-debate transcript →Get the Latest Ligand Pharmaceuticals Incorporated Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeLigand Pharmaceuticals Incorporated Overview
Pro stress-test →Ligand Pharmaceuticals invests in the clinical development and commercialization of high-value medicines while managing one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry with more than 100 partnered commercial and development stage programs. The company maintains and licenses its Captisol® and NITRICIL™ technology platforms to a large network of biopharmaceutical partners, including the world's largest pharmaceutical manufacturers.
Strategic Profile
Pro stress-test →Ligand's business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products, and licensing its technology to partners. The company's outlook for the next five years suggests a compound annual growth rate of at least 23% in royalty receipts, driven by key products like Filspari, Ohtuvayre, and Zelsuvmi.
Competitive Landscape
Pro stress-test →Ligand is a royalty-investing company in various often late-stage biopharmaceutical companies. The company has established multiple alliances and business relationships with world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. Ligand's diversified portfolio and infrastructure-light model differentiate it from traditional pharmaceutical developers focused on internal R&D.
Industry Context
Ligand Pharmaceuticals Incorporated operates in Biopharmaceutical Royalty Investing & Technology Licensing.
Key facts
Headquarters: Jupiter, Florida, US · Revenue: $245-285M guidance (2026)